Sugi Predict

Sugi Predict / Compounds / SCHEMBL12283259

SCHEMBL12283259

SCHEMBL12283259

CC(C)[C@H](NC(=O)OC(C)(C)C)C(=O)NC(CCCNC(N)=O)C(=O)Nc1ccc(CO)cc1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.46
▸ SIRT5 Q9NXA8 1/20 0.44
▸ CA1 P00915 3/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ FURIN P09958 2/20 0.42
▸ BACE1 P56817 2/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ MMP1 P03956 1/20 0.40
▸ MMP3 P08254 1/20 0.40
▸ MMP9 P14780 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20158426 1.00 CA2 (0.46) CA2SIRT5CA1MEN1KMT2A
SCHEMBL17902993 1.00 CA2 (0.46) CA2SIRT5CA1MEN1KMT2A
SCHEMBL13436625 1.00 CA2 (0.46) CA2SIRT5CA1MEN1KMT2A
SCHEMBL14012279 1.00 CA2 (0.46) CA2SIRT5CA1MEN1KMT2A
SCHEMBL24476305 0.93 CA2 (0.46) CA2SIRT5CA1MEN1KMT2A
SCHEMBL17484949 0.93 CA2 (0.46) CA2SIRT5CA1MEN1KMT2A
SCHEMBL23900676 0.92 SIRT5 (0.43) CA2SIRT5CA1FURINBACE1
SCHEMBL23880504 0.92 CA2 (0.51) CA2SIRT5CA1FURINBACE1
SCHEMBL3496034 0.92 SIRT5 (0.48) CA2SIRT5CA1HDAC4HDAC1
SCHEMBL3496030 0.92 SIRT5 (0.48) CA2SIRT5CA1HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11135306-B2 Antibody-drug conjugates CHO Pharma Inc. (TW) 2021-10-05 — — US disclosed
WO-2019217591-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2019-11-14 — — WO disclosed
US-20190328895-A1 ANTIBODY-DRUG CONJUGATES CHO Pharma Inc. (TW) 2019-10-31 — — US disclosed
US-20180133340-A1 ANTIBODY-DRUG CONJUGATES CHO Pharma Inc. (TW) 2018-05-17 — — US disclosed
WO-2011130598-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF SPIROGEN LIMITED (GB) 2011-10-20 — — WO disclosed
US-20100092496-A1 CHEMICAL LINKERS AND CONJUGATES THEREOF MEDAREX, INC. (US) 2010-04-15 — — US disclosed
US-7691962-B2 Chemical linkers and conjugates thereof MEDAREX, INC. (US) 2010-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190328895-A1 ANTIBODY-DRUG CONJUGATES CSGALNACT1, ADCY1, NEU1 CA2 510/4885SIRT5 1999/4885CA1 402/4885
US-20180133340-A1 ANTIBODY-DRUG CONJUGATES CSGALNACT1, ST6GAL1, PA2G4 CA2 552/4885SIRT5 3165/4885CA1 469/4885
US-11135306-B2 Antibody-drug conjugates CSGALNACT1, ST6GAL1, PA2G4 CA2 552/4885SIRT5 3165/4885CA1 469/4885
US-20100092496-A1 CHEMICAL LINKERS AND CONJUGATES THEREOF CLSPN, CD74, ANTXR2 CA2 4082/4885SIRT5 1087/4885CA1 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.